human comp quantikine elisa kit Search Results


quantikine r d systems  (R&D Systems)
93
R&D Systems quantikine r d systems
Quantikine R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/quantikine r d systems/product/R&D Systems
Average 93 stars, based on 1 article reviews
quantikine r d systems - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
human comp elisa kit  (R&D Systems)
99
R&D Systems human comp elisa kit
<t>COMP</t> level is increased in the serum of HCC patients. a <t>ELISA</t> analysis of COMP serum level in 100 HCC patients and 30 healthy controls. P = 0.0115 by t test versus normal controls. b ROC curve of serum COMP in 100 HCC patients and 30 normal controls. c and d The overall survival and disease-free survival of HCC patients with high or low level of COMP estimated using the Kaplan-Meier analysis and compared by the Log-rank test in the same set of patients
Human Comp Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human comp elisa kit/product/R&D Systems
Average 99 stars, based on 1 article reviews
human comp elisa kit - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


COMP level is increased in the serum of HCC patients. a ELISA analysis of COMP serum level in 100 HCC patients and 30 healthy controls. P = 0.0115 by t test versus normal controls. b ROC curve of serum COMP in 100 HCC patients and 30 normal controls. c and d The overall survival and disease-free survival of HCC patients with high or low level of COMP estimated using the Kaplan-Meier analysis and compared by the Log-rank test in the same set of patients

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways

doi: 10.1186/s13046-018-0908-y

Figure Lengend Snippet: COMP level is increased in the serum of HCC patients. a ELISA analysis of COMP serum level in 100 HCC patients and 30 healthy controls. P = 0.0115 by t test versus normal controls. b ROC curve of serum COMP in 100 HCC patients and 30 normal controls. c and d The overall survival and disease-free survival of HCC patients with high or low level of COMP estimated using the Kaplan-Meier analysis and compared by the Log-rank test in the same set of patients

Article Snippet: Quantitative measurement of human COMP in serum of HCC patients were performed by human COMP ELISA kit (R&D System, Minneapolis, MN) following the manufacturer’s protocols.

Techniques: Enzyme-linked Immunosorbent Assay

LX2 cells-derived COMP drives tumor progression. a COMP concentrations (detected by ELISA) in conditioned media (CM) and COMP expression (detected by Western blot) in 5 HCC cell lines and hepatocytes LO2 and activated hepatic stellate cell LX2. LO2 was used as a negative control. n = three independent repeats. P < 0.05 by t test versus LO2. b The marker of activated hepatic stellate cells α-SMA was confirmed using IF. Representative images at × 400 magnification are shown. c The level of COMP in the LX2 and CM was confirmed by Western blot and ELISA after knockdown by siRNAs. The NC siRNA was used as control. n = three independent repeats. P < 0.05 by t test versus control. d The expression of the indicated proteins in HCC cells after co-cultured with LX2 cells after knockdown of COMP were examined by Western blot. β-actin was used as a loading control. Western blot analysis was independently repeated for three times with similar results. e The proposed model by which HSCs-derived COMP promotes HCC progression by activating MEK/ERK and PI3K/AKT signaling pathway via a CD36-dependent manner. ( *P < 0.05 , **P < 0.01)

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways

doi: 10.1186/s13046-018-0908-y

Figure Lengend Snippet: LX2 cells-derived COMP drives tumor progression. a COMP concentrations (detected by ELISA) in conditioned media (CM) and COMP expression (detected by Western blot) in 5 HCC cell lines and hepatocytes LO2 and activated hepatic stellate cell LX2. LO2 was used as a negative control. n = three independent repeats. P < 0.05 by t test versus LO2. b The marker of activated hepatic stellate cells α-SMA was confirmed using IF. Representative images at × 400 magnification are shown. c The level of COMP in the LX2 and CM was confirmed by Western blot and ELISA after knockdown by siRNAs. The NC siRNA was used as control. n = three independent repeats. P < 0.05 by t test versus control. d The expression of the indicated proteins in HCC cells after co-cultured with LX2 cells after knockdown of COMP were examined by Western blot. β-actin was used as a loading control. Western blot analysis was independently repeated for three times with similar results. e The proposed model by which HSCs-derived COMP promotes HCC progression by activating MEK/ERK and PI3K/AKT signaling pathway via a CD36-dependent manner. ( *P < 0.05 , **P < 0.01)

Article Snippet: Quantitative measurement of human COMP in serum of HCC patients were performed by human COMP ELISA kit (R&D System, Minneapolis, MN) following the manufacturer’s protocols.

Techniques: Derivative Assay, Enzyme-linked Immunosorbent Assay, Expressing, Western Blot, Negative Control, Marker, Knockdown, Control, Cell Culture